WO2013027681A1 - 貼付剤 - Google Patents
貼付剤 Download PDFInfo
- Publication number
- WO2013027681A1 WO2013027681A1 PCT/JP2012/070933 JP2012070933W WO2013027681A1 WO 2013027681 A1 WO2013027681 A1 WO 2013027681A1 JP 2012070933 W JP2012070933 W JP 2012070933W WO 2013027681 A1 WO2013027681 A1 WO 2013027681A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- liquid
- patch
- weight
- adhesive layer
- risperidone
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Definitions
- the present invention relates to a patch containing risperidone or a salt thereof. More specifically, the present invention relates to a patch having a high skin permeability of risperidone or a salt thereof and good percutaneous absorption.
- the drug is mixed with an adhesive base or the like to form a patch.
- a tape agent having higher adhesiveness is often used than a cataplasm containing a large amount of water as a constituent component in a patch.
- a lipophilic adhesive base such as rubber, acrylic or silicone is used.
- rubber-based adhesive bases are widely used because additives can be easily blended as compared with other adhesive bases (Patent Documents 1 to 3).
- Patent Documents 1 to 3 Even in a patch using a rubber-based adhesive base, there is a problem that sufficient drug release cannot be secured or skin irritation caused by a tackifier usually added to the patch occurs. It was pointed out.
- schizophrenia is a mental disorder characterized by fundamental and characteristic distortions of thinking and perception, inappropriate and dull emotions, positive symptoms such as delusions, hallucinations, paranoia, and social withdrawal It is characterized by negative symptoms such as emotional bluntness. Signs of schizophrenia generally develop between the ages of 16 and 25 and occur in 1 in 100 people worldwide. It is more common than Alzheimer's disease, multiple sclerosis, insulin-dependent diabetes and muscular dystrophy. It is known that early visits and treatments can provide recovery or significant improvement in symptoms, and early therapeutic intervention can avoid costly hospitalizations.
- risperidone As an effective drug for the treatment of schizophrenia, risperidone, ie, 3- [2- [4- (6-fluoro-1,2-benzisoxazol-3-yl) -1-piperidinyl] ethyl] -6 , 7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one is known (Patent Document 4).
- the effect of risperidone on schizophrenia is thought to be mainly due to central nervous system regulation based on dopamine D 2 receptor antagonism and serotonin 5-HT 2 receptor antagonism. Widely used.
- This risperidone is conventionally administered orally and marketed in dosage forms such as tablets, fine granules, and liquids.
- antipsychotic drugs such as risperidone by methods other than oral administration. Therefore, development of a new administration method of risperidone has been attempted, and development of a transdermal therapeutic absorption system (TTS) has been attempted in addition to oral administration (Patent Documents 5 and 6).
- Patent Document 5 discloses a medical patch for transdermal administration containing fatty acids, fatty acid monoglycerides and the like as a skin penetration enhancer
- Patent Document 6 discloses alcohols, polyhydric alcohols, higher alkanes, higher fatty acids
- a transdermal preparation containing a higher fatty acid ester or the like as a transdermal absorption enhancer is disclosed.
- the release of risperidone from the preparation, skin permeability, and the like are not sufficient, and thus the effect of TTS has not been sufficiently shown and has not been put into practical use.
- Patent Documents 7 and 8 As a melting point depressant for basic drugs such as risperidone, an improvement in transdermal absorbability has been attempted by adding an organic acid or a salt thereof to the patch (Patent Documents 7 and 8). However, when an organic acid or a salt thereof is added, the skin irritation of the patch may be increased.
- An object of the present invention is to provide a patch having sufficient adhesiveness and low skin irritation, having good skin permeability of risperidone or a salt thereof, and exhibiting sufficient transdermal absorbability. .
- the present inventors have used a thermoplastic elastomer and a large amount of a liquid component for the elastomer as an adhesive base, so that no tackifier is contained.
- Risperidone that can reduce skin irritation while having sufficient adhesiveness, and when risperidone or a salt thereof is contained, shows good skin permeability and exhibits sufficient transdermal absorption. Or it discovered that the patch of the salt was obtained, and came to complete this invention.
- the present invention relates to the following (1) to (11).
- a patch in which an adhesive layer for holding a drug is formed on a support the adhesive layer comprising a thermoplastic elastomer, a liquid component exceeding 300 parts by weight relative to 100 parts by weight of the elastomer, and risperidone Or the patch which contains the salt and may contain the tackifier, and the content in the adhesion layer is 10 weight% or less.
- the liquid component contains one or more selected from the group consisting of a non-volatile hydrocarbon oil, a liquid surfactant, an ester solvent, an alcohol solvent and an amide solvent (1) ).
- the patch of the present invention has sufficient adhesiveness when applied to the skin, has reduced skin irritation, has good skin permeability of risperidone or a salt thereof, and has excellent transdermal absorbability.
- FIG. 3 is a graph showing the skin permeability of risperidone in the patches of Examples 1 to 3 of the present invention. It is a graph which shows the skin permeability of risperidone in the patch of Example 4 of this invention and the patch of the comparative example 2.
- FIG. It is a graph which shows the transdermal absorbability of the patch of Example 3 of this invention.
- an adhesive layer for holding a drug is formed on a support, and the adhesive layer comprises a thermoplastic elastomer, a liquid component exceeding 300 parts by weight with respect to 100 parts by weight of the elastomer, and risperidone.
- the salt is included, and the tackifier may be included,
- the content in the adhesion layer is 10 weight% or less, It is characterized by the above-mentioned.
- thermoplastic elastomer used in the present invention is an elastomer that exhibits fluidity when softened and exhibits fluidity, and returns to a rubber-like elastic body when cooled.
- styrene-based thermoplastic elastomers, particularly styrene-based block copolymers are preferably used from the viewpoint of achieving sufficient tackiness and reducing skin irritation, both of which are the objects of the present invention.
- styrene block copolymers include styrene-butadiene block copolymers, styrene-butadiene-styrene block copolymers, styrene-isoprene block copolymers, styrene-isoprene-styrene block copolymers, and styrene- Ethylene / butylene block copolymer, styrene-ethylene / butylene-styrene block copolymer, styrene-ethylene / propylene block copolymer, styrene-ethylene / propylene-styrene block copolymer, styrene-isobutylene block copolymer, Examples thereof include a styrene-isobutylene-styrene block copolymer.
- ethylene / butylene represents a copolymer block of ethylene and butylene
- ethylene / propylene represents a copolymer block of ethylene and propylene
- styrene block copolymers styrene-isoprene-styrene block copolymers and styrene-isoprene blocks are used from the viewpoints of both adhesiveness and low skin irritation, as well as the availability and handling of patch products.
- One or more selected from the group consisting of copolymers are particularly preferably used.
- the styrene-isoprene-styrene block copolymer preferably has a styrene unit content in the copolymer of 5% to 60% by weight, preferably 10% to 50% by weight. Some are more preferred. Further, those having a weight average molecular weight measured by gel filtration chromatography of 20,000 to 500,000 are preferred, and those having a weight average molecular weight of 30,000 to 300,000 are more preferred.
- the styrene-isoprene block copolymer preferably has a styrene unit content of 5 to 50% by weight, more preferably 10 to 40% by weight. Further, those having a weight average molecular weight measured by gel filtration chromatography of 10,000 to 500,000 are preferred, and those having a weight average molecular weight of 20,000 to 300,000 are more preferred.
- styrene-isoprene-styrene block copolymer or a styrene-isoprene block copolymer a copolymer produced by a method known per se can be used, but a commercial product satisfying the above characteristics, for example, “KRATON”. D ”(manufactured by KRATON POLYMERS),“ JSR SIS ”(manufactured by JSR) and the like can also be used.
- the “liquid component” is a liquid at room temperature and does not evaporate during production, storage and application, and remains in the adhesive layer. Or the thing added as a dispersing agent of the salt and / or a percutaneous absorption enhancer.
- “normal temperature” means 15 ° C. to 25 ° C. Therefore, the liquid component is a substance having a melting point at a temperature lower than normal temperature and a boiling point of preferably 150 ° C. or higher, more preferably 170 ° C. or higher.
- what has a certain amount of viscosity can also be used.
- the “liquid component” of the present invention those having a viscosity at 25 ° C. of 0.01 mPa ⁇ s to 1,000,000 mPa ⁇ s can be used.
- liquid component examples include nonvolatile hydrocarbons, liquid surfactants, ester solvents, alcohol solvents, amide solvents, and the like.
- Non-volatile hydrocarbons are preferably chain saturated hydrocarbons having about 20 to 40 carbon atoms or chain unsaturated hydrocarbons having about 20 to 40 carbon atoms such as liquid paraffin, squalene, squalane, pristane and the like. It is done. Of these, liquid paraffin is more preferable.
- the liquid paraffin is a colorless and odorless liquid mixture of alkanes having 20 or more carbon atoms.
- a liquid paraffin that conforms to the standards prescribed in the Japanese Pharmacopoeia, the US Pharmacopoeia, and the like can be preferably used.
- Liquid surfactant refers to a surfactant that is liquid at room temperature.
- Such surfactants include polyoxyethylene fatty acid esters such as polyoxyethylene (10) monolaurate that are liquid at normal temperature, polyoxyethylene sorbites that are liquid at normal temperature such as polyoxyethylene (6-60) sorbit tetraoleate, and the like.
- Fatty acid ester polyoxyethylene (20) sorbitan monooleate, polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monopalmitate, etc., liquid polyoxyethylene sorbitan fatty acid ester, sorbitan mono Sorbitan fatty acid ester, glycerin monooleate, polyoxyethylene (3-10) castor oil derivatives that are liquid at room temperature such as laurate, sorbitan monooleate, sorbitan sesquioleate, sorbitan trioleate, Polyoxyls of liquid form at room temperature such as glycerin fatty acid ester, polyoxyethylene (2-9) lauryl ether, polyoxyethylene (2-7) oleyl ether, etc., which are liquid at room temperature, such as reoxyethylene (5-20) hydrogenated castor oil Polyoxyethylene poly (ethylene oxide) which is liquid at room temperature such as polyoxyethylene alkylphenyl ether, Pluronic L-31, Pluronic L-44, etc
- sorbitan fatty acid esters which are liquid at room temperature are more preferred, and sorbitan monolaurate is particularly preferred in order to enhance transdermal absorbability.
- the content of the surfactant in the adhesive layer is preferably 0.01% to 10% by weight, more preferably 0.1% to 5% by weight, based on the total weight of the adhesive layer.
- ester solvent examples include esters of long-chain fatty acids and monovalent aliphatic alcohols, medium-chain fatty acid triglycerides, esters of polyvalent carboxylic acids and monovalent aliphatic alcohols, and carbonates.
- the ester of a long chain fatty acid and a monovalent aliphatic alcohol is preferably an ester liquid at room temperature of a long chain saturated fatty acid having 12 to 20 carbon atoms and a monovalent aliphatic alcohol having 1 to 20 carbon atoms.
- Room temperature liquid such as ethyl myristate, isopropyl myristate, octyldodecyl myristate liquid at room temperature such as ethyl myristate, ethyl palmitate, isopropyl palmitate, isostearyl palmitate, etc.
- Room temperature such as palmitic acid ester, isopropyl stearate, etc. And liquid stearates.
- An ester of a long-chain unsaturated fatty acid having 12 to 20 carbon atoms and a monovalent aliphatic alcohol having 1 to 20 carbon atoms can also be preferably used.
- examples thereof include oleic acid esters that are liquid at normal temperature, ethyl linoleate, isopropyl linoleate, and other linoleic acid esters that are liquid at normal temperatures.
- the medium chain fatty acid triglyceride is a triglyceride composed of a fatty acid having about 6 to 12 carbon atoms such as caproic acid, caprylic acid, capric acid, lauric acid, and glycerin.
- a triglyceride mixture of acid and capric acid, a triglyceride mixture of caprylic acid, capric acid and lauric acid, and the like can be used.
- liquid fats and oils can also be used at normal temperature containing many of these. Examples of such fats and oils include peanut oil, olive oil, castor oil and the like.
- products that are commercially available for pharmaceuticals can be used as medium-chain fatty acid triglycerides that are liquid at room temperature or oils containing medium-chain fatty acid triglycerides that are liquid at room temperature.
- esters of polyvalent carboxylic acids and monovalent aliphatic alcohols include, for example, liquid adipic acid diesters such as diethyl adipate and diisopropyl adipate, diethyl sebacate, diisopropyl sebacate, dioctyldodecyl sebacate and the like
- a diester that is liquid at room temperature with a dicarboxylic acid having 2 to 12 carbon atoms and a monovalent aliphatic alcohol having 1 to 20 carbon atoms, such as sebacic acid diester that is liquid at normal temperature, can be given.
- carbonic acid ester examples include cyclic carbonic acid esters of carbonic acid and diols having 2 to 10 carbon atoms, such as ethylene carbonate, propylene carbonate, vinylene carbonate, and propylene carbonate is preferred.
- myristic acid ester, medium chain fatty acid triglyceride mixture, sebacic acid ester and carbonate ester are preferable, and isopropyl myristate, caprylic acid and capric acid triglyceride mixture, diethyl sebacate and propylene carbonate are more preferable. .
- alcohol solvents include higher saturated aliphatic alcohols that are liquid at room temperature of about 12 to 20 carbon atoms such as lauryl alcohol, isostearyl alcohol, and 2-octyldodecanol; and about 12 to 20 carbon atoms such as oleyl alcohol.
- higher unsaturated aliphatic alcohols that are liquid at normal temperature
- polyhydric alcohols that are liquid at normal temperature such as ethylene glycol, propylene glycol, glycerin, 1,3-butanediol, and polyethylene glycol having a molecular weight of about 100 to 600.
- polyhydric alcohols that are liquid at room temperature such as ethylene glycol, propylene glycol, glycerin, 1,3-butanediol, and polyethylene glycol are preferred.
- Ethylene glycol, propylene glycol, 1,3-butanediol, and a molecular weight of about 100 to 600 are preferable.
- a diol that is liquid at room temperature such as polyethylene glycol is more preferable.
- amide solvents include pyrrolidone such as N-methyl-2-pyrrolidone and 2-pyrrolidone; imidazolidinone such as 1,3-dimethyl-2-imidazolidinone; formamide, N-methylformamide, N, N— Examples include alkaneamides such as dimethylformamide, N-methylacetamide, N, N-dimethylacetamide, and N-methylpropanamide; phosphoramides such as hexamethylphosphoric triamide. Of the amide solvents, N-methyl-2-pyrrolidone, N, N-dimethylformamide, and N, N-dimethylacetamide are preferable, and N-methyl-2-pyrrolidone is more preferable.
- the liquid component contains a non-volatile hydrocarbon oil, particularly liquid paraffin.
- the non-volatile hydrocarbon oil is used together with other liquid components. It is preferable to contain.
- the content of the non-volatile hydrocarbon oil such as liquid paraffin in the adhesive layer is usually 12 to 92.5% by weight, preferably 15 to 90% by weight, more preferably 20 to 80% by weight. is there.
- the content of the non-volatile hydrocarbon oil in the total weight of the liquid component is preferably 20% by weight to 97% by weight, more preferably 30% by weight to 90% by weight.
- the liquid component is preferably a liquid hydrocarbon, non-volatile hydrocarbon oil such as liquid paraffin, a liquid surfactant, ester solvent, alcohol. It is preferable to include one or more selected from the group consisting of a system solvent and an amide solvent. In particular, it is possible to improve transdermal absorbability by using one or more ester solvents in combination with one or more selected from the group consisting of alcohol solvents and amide solvents. In particular, the weight ratio of (one or more of ester solvents): (one or more selected from the group consisting of alcohol solvents and amide solvents) is 1: 1. A ratio of ⁇ 1: 4 is preferable for enhancing the effect of improving transdermal absorbability.
- the content of one or more selected from the group consisting of a liquid surfactant, an ester solvent, an alcohol solvent and an amide solvent is preferably a total of these, relative to the total weight of the liquid component Is 3 to 80% by weight, more preferably 10 to 70% by weight, preferably 2 to 75% by weight, more preferably 7 to 65% by weight based on the total weight of the adhesive layer. is there.
- the patch of the present invention contains the above liquid component in a total amount exceeding 300 parts by weight with respect to 100 parts by weight of the thermoplastic elastomer.
- the content of the liquid component with respect to 100 parts by weight of the thermoplastic elastomer is 300 parts by weight or less, sufficient adhesiveness cannot be obtained.
- the upper limit of the content of the liquid component usually does not exceed 1500 parts by weight with respect to 100 parts by weight of the thermoplastic elastomer.
- the content of the liquid component with respect to 100 parts by weight of the thermoplastic elastomer is preferably 320 parts by weight to 1000 parts by weight, more preferably 340 parts by weight to 700 parts by weight.
- the content of the thermoplastic elastomer in the adhesive layer of the patch of the present invention is usually 5% to 24.7% by weight, preferably 8% to 24% by weight, more preferably 10% to 23%. % By weight.
- the content of the liquid component in the adhesive layer is usually 60% to 94.9% by weight, preferably 65% to 91.9% by weight, and more preferably 70% to 89.9% by weight. More preferably, it is 72 wt% to 88 wt%, particularly preferably 75 wt% to 85 wt%.
- the adhesive layer can contain a thermoplastic elastomer and a liquid component at the content and content ratio as described above to achieve good adhesiveness.
- the tackifier is a resin generally used for imparting tackiness in the field of patches, and includes, for example, rosin resins, polyterpene resins, coumarone-indene resins, petroleum resins, terpene-phenol resins, Examples include alicyclic saturated hydrocarbon resins.
- the content of the tackifier in the adhesive layer is 10% by weight or less based on the total weight of the adhesive layer.
- the content is preferably 5% by weight or less, more preferably 2% by weight or less, still more preferably 1% by weight or less, and most preferably no tackifier.
- content of a tackifier is adjusted according to the kind of thermoplastic elastomer and a liquid component, content, and its content ratio.
- risperidone can also be used in the form of a transdermally absorbable salt.
- risperidone salts include acid addition salts, hydrohalic acids such as hydrochloric acid and hydrobromic acid, addition salts of inorganic acids such as sulfuric acid, nitric acid and phosphoric acid, acetic acid, propionic acid, butyric acid and the like.
- the content of risperidone or a salt thereof in the patch is not particularly limited, but preferably 0.1% by weight to 10% with respect to the total weight of the adhesive layer in consideration of dispersibility and transdermal absorbability in the adhesive layer. % By weight, particularly preferably 0.5% by weight to 8% by weight.
- excipient in the adhesive layer forming the patch of the present invention, as an optional component, excipient, dispersant, stabilizer, thickener, antioxidant, softener, flavoring agent, colorant, solid at room temperature You may contain common additives, such as surfactant.
- excipient used in the present invention examples include silicon compounds such as silicic anhydride, light silicic anhydride, and hydrous silicic acid; cellulose derivatives such as ethyl cellulose, methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose; Synthetic water-soluble polymers; aluminum compounds such as dry aluminum hydroxide gel and hydrous aluminum silicate; pigments such as kaolin and titanium oxide.
- dispersant used in the present invention examples include gum arabic, propylene glycol alginate, sodium dioctyl sulfosuccinate, lecithin and the like.
- Examples of the stabilizer used in the present invention include zinc stearate, gelatin, dextran, povidone and the like.
- Examples of the thickener used in the present invention include carboxyvinyl polymer and tragacanth.
- antioxidant used in the present invention examples include dibutylhydroxytoluene, ascorbic acid, tocopherol, tocopherol acetate, butylhydroxyanisole, and 2-mercaptobenzimidazole.
- softening agent used in the present invention examples include polyisoprene rubber and polybutene.
- Examples of the flavoring agent used in the present invention include d-camphor, dl-camphor, cinnamaldehyde, mint oil, dl-menthol, and l-menthol.
- Examples of the colorant used in the present invention include yellow iron oxide, yellow ferric oxide, carbon black and the like.
- the patch of the present invention is prepared by spreading an adhesive layer having the above structure on a support.
- the “support” is not particularly limited, and a general-purpose one can be used.
- stretchable or non-stretchable woven fabrics such as polyethylene and polypropylene, non-woven fabrics, polyesters such as polyethylene, polypropylene, and polyethylene terephthalate, ethylene vinyl acetate copolymers, films such as vinyl chloride, and foaming properties such as urethane and polyurethane A support is mentioned. These may be used alone or may be a laminate of a plurality of types.
- an antistatic agent may be contained in the woven fabric, non-woven fabric, film, etc. constituting the support.
- a nonwoven fabric or a woven fabric, or a laminate of these with a film can be used as the support.
- the thickness of the support is usually 10 ⁇ m to 100 ⁇ m, preferably 15 ⁇ m to 50 ⁇ m for a film, and usually 50 ⁇ m to 2,000 ⁇ m, preferably 100 ⁇ m to 100 ⁇ m for porous sheets such as woven fabrics, non-woven fabrics and foamed supports. 1,000 ⁇ m.
- the patch of the present invention can also be provided with a release liner that is common in the field of patches.
- a release liner glassine paper, polyethylene, polypropylene, polyester, polyethylene terephthalate, polystyrene, aluminum film, foamed polyethylene film or foamed polypropylene film, or a laminate of two or more of the above can be used. Silicone-processed, fluororesin-processed, embossed, etc. can also be used.
- the thickness of the release liner is usually 10 ⁇ m to 200 ⁇ m, preferably 15 ⁇ m to 150 ⁇ m.
- the patch of the present invention can be obtained, for example, by dissolving a thermoplastic elastomer and risperidone or a salt thereof in a liquid component and dissolving or dispersing them in a solvent such as toluene to prepare a coating solution for forming an adhesive layer.
- the coating liquid can be applied to a support and then dried.
- the release liner can be pressure-bonded to the adhesive layer and laminated.
- the coating liquid may be applied onto a release liner, dried to form an adhesive layer on the surface of the release liner, and then the support may be pressure bonded onto the adhesive layer and bonded together.
- the coating solution for forming the adhesive layer uses, for example, a conventional coater such as a roll coater, die coater, gravure roll coater, reverse roll coater, kiss roll coater, dip roll coater, bar coater, knife coater, spray coater, etc. Can be done.
- the coating liquid is preferably dried under heating, for example, at a temperature of about 40 ° C. to 150 ° C.
- the pressure-sensitive adhesive layer containing risperidone or a salt thereof after drying is preferably 10 g / m 2 to 1,000 g / m 2 , more preferably 20 g / m 2 to 800 g / m 2 .
- the coating solution was applied to a silicone-treated polyethylene terephthalate (PET) film (release liner) and adjusted so that the weight of the adhesive layer after drying was 100 g / m 2 . After drying in an oven at 80 ° C. for 30 minutes, a film (support) made of polyethylene terephthalate (PET) is laminated on the surface of the adhesive layer, and cut into a size of 15 cm ⁇ 30 cm to obtain a target patch. It was.
- PET polyethylene terephthalate
- Example 4 and Comparative Example 2 Preparation of patch containing risperidone According to the formulation shown in Table 2, the target patch was prepared in the same manner as in Examples 1 to 3.
- a pinene polymer (“YS Resin PXN1150N”, manufactured by Yasuhara Chemical Co., Ltd.) was used as a tackifier.
- each patch of Examples 1 to 3 of the present invention was excellent in the skin permeability of risperidone.
- good skin permeability was observed in the patches of Examples 2 and 3 in which the liquid paraffin content per liquid component was 40 wt% and 55 wt%.
- FIG. 2 shows that the patch of Example 4 of the present invention has better skin permeability than the patch of Comparative Example 2 containing 30% by weight of a tackifier.
- Example 2 In vivo transdermal absorbability test The patch of Example 3 was cut to 4 cm x 6 cm to prepare a sample, which was applied to the back of five slc / HWY male hairless rats (7 weeks old). 3, 6, 9, 24, 48 and 72 hours after application, blood was collected from the jugular vein and centrifuged to obtain plasma. The concentration of risperidone in the obtained plasma was measured by liquid chromatography-tandem mass spectrometry (LC-MS / MS). The measurement conditions for LC-MS / MS are as follows. ⁇ HPLC conditions> HPLC system: high performance liquid chromatograph (1200Series) Agilent Technologies, Inc. Analytical column: Atlantic dc18, 2.1 mm I.D. D.
- the results of the transdermal absorbability test are shown in FIG. From FIG. 3, it was shown that risperidone was absorbed percutaneously immediately after being applied to the skin and transferred into the blood. In addition, during the continuous application period of 3 days, the concentration of risperidone in plasma is maintained at about 1,000 ng / mL on average, and risperidone is absorbed percutaneously for a long time in the patch of the present invention. It has been shown.
- Example 3 Primary skin irritation test The patch of Example 3 was cut into 2.5 cm x 2.5 cm as a sample, and 24 on the back of a white male rabbit (Kbs: NZW) whose hair was removed with an electric clipper. Time occlusion was applied. After 1, 24, 48 and 72 hours have passed after peeling the sample, Draize. J. et al. H. The skin condition was evaluated by the above-mentioned method (see J. Pharmacol. Exp. Ther. 82 377-390). I. I. The value was calculated. As a result, P.I. I. I. The value was 1.0, which was an evaluation that weak skin irritation was observed, and it was revealed that the skin patch had a low level of skin irritation.
- a patch that has sufficient adhesiveness when applied to the skin, has reduced skin irritation, has good skin permeability of risperidone or a salt thereof, and has excellent transdermal absorbability. can do. Accordingly, it is possible to provide a risperidone or a salt-containing preparation thereof that can be used as a new therapeutic agent for schizophrenia administered by a route other than oral.
Abstract
Description
しかし、ゴム系の粘着基剤を用いた貼付剤においても、充分な薬物の放出性が確保できない、あるいは貼付剤に通常添加されている粘着付与剤に起因する皮膚刺激が発生する等の問題が指摘されていた。
そこで、リスペリドンの新たな投与方法の開拓が試みられ、経口投与以外に経皮治療吸収システム(TTS)の開発が試みられている(特許文献5、6)。特許文献5には、脂肪酸類、脂肪酸モノグリセリド等を皮膚浸透促進剤として含む経皮投与用の医療用パッチが開示され、特許文献6には、アルコール類、多価アルコール、高級アルカン、高級脂肪酸、高級脂肪酸エステル等を経皮吸収促進剤として含有する経皮適用製剤が開示されている。しかしながら、これらの経皮吸収製剤においては、製剤からのリスペリドンの放出、皮膚透過性等が十分ではないため、TTSの効果が十分に示されておらず、実用化には至っていない。
(1)支持体上に薬物を保持する粘着層が形成された貼付剤であって、前記粘着層は、熱可塑性エラストマー、該エラストマー100重量部に対して300重量部を超える液状成分、およびリスペリドンまたはその塩を含み、かつ、粘着付与剤を含んでいてもよく、その粘着層中における含有量が10重量%以下である、貼付剤。
(2)液状成分として、不揮発性炭化水素油、液状の界面活性剤、エステル系溶媒、アルコール系溶媒およびアミド系溶媒よりなる群から選択される1種又は2種以上を含有する、上記(1)に記載の貼付剤。
(3)液状成分として、不揮発性炭化水素油と、不揮発性炭化水素油以外の液状成分とを含有する、上記(1)に記載の貼付剤。
(4)不揮発性炭化水素油が流動パラフィンである、上記(2)または(3)に記載の貼付剤。
(5)不揮発性炭化水素油以外の液状成分として、液状の界面活性剤、エステル系溶媒、アルコール系溶媒およびアミド系溶媒よりなる群から選択される1種又は2種以上を含有する、上記(3)に記載の貼付剤。
(6)不揮発性炭化水素油以外の液状成分として、エステル系溶媒の1種または2種以上と、アルコール系溶媒およびアミド系溶媒よりなる群から選択される1種又は2種以上とを含有する、上記(3)に記載の貼付剤。
(7)液状の界面活性剤が液状のソルビタン脂肪酸エステルである、上記(2)または(5)に記載の貼付剤。
(8)粘着層中の液状成分含有量が60重量%以上である、上記(1)~(7)のいずれかに記載の貼付剤。
(9)熱可塑性エラストマーがスチレン系ブロック共重合体である、上記(1)~(8)のいずれかに記載の貼付剤。
(10)スチレン系ブロック共重合体が、スチレン-イソプレン-スチレンブロック共重合体およびスチレン-イソプレンブロック共重合体よりなる群から選択される1種又は2種以上である、上記(9)に記載の貼付剤。
(11)粘着層中に粘着付与剤を含まない、上記(1)~(10)のいずれかに記載の貼付剤。
かかる界面活性剤としては、ポリオキシエチレン(10)モノラウレート等の常温で液状のポリオキシエチレン脂肪酸エステル、ポリオキシエチレン(6~60)ソルビットテトラオレエート等の常温で液状のポリオキシエチレンソルビット脂肪酸エステル、ポリオキシエチレン(20)ソルビタンモノオレエート、ポリオキシエチレン(20)ソルビタンモノラウレート、ポリオキシエチレン(20)ソルビタンモノパルミテート等の常温で液状のポリオキシエチレンソルビタン脂肪酸エステル、ソルビタンモノラウレート、ソルビタンモノオレエート、ソルビタンセスキオレエート、ソルビタントリオレエート等の常温で液状のソルビタン脂肪酸エステル、グリセリンモノオレエート、ポリオキシエチレン(3~10)ヒマシ油誘導体、ポリオキシエチレン(5~20)硬化ヒマシ油等の常温で液状のグリセリン脂肪酸エステル、ポリオキシエチレン(2~9)ラウリルエーテル、ポリオキシエチレン(2~7)オレイルエーテル等の常温で液状のポリオキシエチレン高級脂肪族アルコールエーテル、ポリオキシエチレン(2~15)ノニルフェニルエーテル等の常温で液状のポリオキシエチレンアルキルフェニルエーテル、プルロニックL-31、プルロニックL-44等の常温で液状のポリオキシエチレンポリオキシプロピレン共重合体などの常温で液状のノニオン性界面活性剤が挙げられる。
なお、本発明においては、常温で液状の中鎖脂肪酸トリグリセリド、または常温で液状の中鎖脂肪酸トリグリセリド含有油脂として、医薬品用として市販されている製品を用いることもできる。
なかでも、エチレングリコール、プロピレングリコール、グリセリン、1,3-ブタンジオール、ポリエチレングリコール等の常温で液状の多価アルコールが好ましく、エチレングリコール、プロピレングリコール、1,3-ブタンジオール、分子量100~600程度のポリエチレングリコール等の常温で液状のジオールがより好ましい。
上記アミド系溶媒のうち、N-メチル-2-ピロリドン、N,N-ジメチルホルムアミド、N,N-ジメチルアセトアミドが好ましく、N-メチル-2-ピロリドンがより好ましい。
ここで粘着付与剤は、通常貼付剤の分野で粘着性を付与するために汎用される樹脂であって、たとえばロジン系樹脂、ポリテルペン樹脂、クマロン-インデン樹脂、石油系樹脂、テルペン-フェノール樹脂、脂環族飽和炭化水素樹脂等が挙げられる。
本発明の貼付剤においては、入手のしやすさおよび粘着層における分散性等の観点から、特に好ましくは遊離型のリスペリドンが用いられる。
本発明において「支持体」としては、特に限定されず、汎用のものを使用できる。たとえば、ポリエチレン、ポリプロピレン等の伸縮性又は非伸縮性の織布、不織布、ポリエチレン、ポリプロピレン、ポリエチレンテレフタレート等のポリエステル、エチレン酢酸ビニル共重合体、塩化ビニル等のフィルム、あるいはウレタン、ポリウレタン等の発泡性支持体が挙げられる。これらは、単独で使用してもよく、複数種が積層されたものを使用してもよい。さらに、支持体に静電気が蓄積することを防止するため、支持体を構成する前記織布、不織布、フィルム等に帯電防止剤を含有させてもよい。また、粘着層との良好な投錨性を得るため、支持体として不織布もしくは織布、またはこれらとフィルムの積層体を用いることができる。支持体の厚さは、フィルムについては通常10μm~100μm、好ましくは15μm~50μmであり、織布、不織布、発泡性支持体等の多孔性シートについては通常50μm~2,000μm、好ましくは100μm~1,000μmである。
表1に示す処方に従って、粘着層を構成する各成分を秤取した。まず、流動パラフィン(「KAYDOL」、Sonneborn社製)にスチレン-イソプレン-スチレンブロック共重合体(「JSR SIS5002」、JSR社製)を加え、粘着層成分の全含有量100重量部に対し、60.0重量部のトルエンに溶解する。前記溶解液に対し、リスペリドンをその他の液状成分に溶解して加えて混合攪拌し、粘着層形成用の塗液を調製した。
上記塗液を、シリコーン処理したポリエチレンテレフタレート(PET)製フィルム(剥離ライナー)に塗布し、乾燥後の粘着層重量が100g/m2となるように調整した。80℃のオーブンにて30分乾燥後、該粘着層の表面に、ポリエチレンテレフタレート(PET)製フィルム(支持体)をラミネートし、15cm×30cmの大きさに裁断して、目的の貼付剤を得た。
表1の実施例3の処方において、スチレン-イソプレン-スチレンブロック共重合体に替えて、市販の架橋カルボキシル官能性アクリル系粘着剤(「Durotak 87-2194」、ヘンケル社製、固形分含有量=40重量%)を、固形分含有量が表1の熱可塑性エラストマー含有量と同じになるように秤取して流動パラフィンを添加し、リスペリドンをその他の液状成分に溶解して加えて混合攪拌し、粘着層形成用の塗液を調製した。
該塗液をシリコーン処理したPET製フィルム(剥離ライナー)に塗布し、乾燥後の粘着層重量が100g/m2となるように調整し、80℃のオーブンにて60分乾燥したが、硬化せず、貼付剤は得られなかった。
表2に示す処方に従って、実施例1~3と同様にして目的の貼付剤を調製した。なお、比較例2の貼付剤において、粘着付与剤としてピネン重合体(「YSレジン PXN1150N」、ヤスハラケミカル株式会社製)を用いた。
特許文献7に記載された方法に準じて、Wister系雄性ラット(5週齢)の腹部抽出皮膚を縦型フランツ拡散セルに装着した。実施例1~4および比較例2の各貼付剤をそれぞれ直径1.0cmの円形に打ち抜いて試料とし、拡散セルのラット皮膚上に貼付した(n=3)。レセプター層には10容量%エタノール生理食塩水を用いて、経時的にレセプター溶液中のリスペリドン含有量を高速液体クロマトグラフィー(HPLC)により定量した。HPLCの定量条件を以下に示す。
<HPLC条件>
HPLCシステム:高速液体クロマトグラフ(LC2010C) 株式会社島津製作所製
カラム:ODS、4.6mmφ×15cm、5μm
カラム温度:40℃
移動層:0.1重量%リン酸水溶液/メタノール/アセトニトリル/SDS=4/1/5/0.01(体積比)
検出波長:254nm
流量:0.7mL/分
実施例3の貼付剤を4cm×6cmにカットして試料とし、slc/HWY系雄性へアレスラット(7週齢)5匹の背部に貼付した。貼付後、3、6、9、24、48および72時間後に頸静脈より採血し、遠心分離して血漿を得た。得られた血漿中のリスペリドン濃度を、液体クロマトグラフィー-タンデム型質量分析法(LC-MS/MS)にて測定した。LC-MS/MSの測定条件は以下の通りである。
<HPLC条件>
HPLCシステム:高速液体クロマトグラフ(1200Series) Agilent Technologies社製
分析カラム:Atlantis dc18、2.1mmI.D.×150mm、5μm
カラム温度:40℃
移動層:メタノール/0.05重量%ギ酸溶液=1/1(体積比)
流量:0.2mL/分
<MS/MS条件>
タンデム質量分析計:API4000、AB Sciex Pte社製
インターフェース:Turbo-V spray
イオン化法:ESI、正イオンモード
測定イオン:リスペリドン 422.6 191.4
実施例3の貼付剤を2.5cm×2.5cmにカットして試料とし、電気バリカンで除毛した白色雄性家兎(Kbs:NZW)の背部に24時間閉塞貼付した。試料を剥離した後、1、24、48および72時間経過後に、Draize.J.H.らの方法(J. Pharmacol. Exp. Ther. 82 377-390参照)により皮膚の状態を評価し、一次刺激指数P.I.I.値を算出した。その結果、P.I.I.値は1.0で、弱い皮膚刺激性が認められるとの評価であり、貼付剤としては、皮膚刺激性が低いレベルであることが明らかとなった。
Claims (11)
- 支持体上に薬物を保持する粘着層が形成された貼付剤であって、前記粘着層は、熱可塑性エラストマー、該エラストマー100重量部に対して300重量部を超える液状成分、およびリスペリドンまたはその塩を含み、かつ、粘着付与剤を含んでいてもよく、その粘着層中における含有量が10重量%以下である、貼付剤。
- 液状成分として、不揮発性炭化水素油、液状の界面活性剤、エステル系溶媒、アルコール系溶媒およびアミド系溶媒よりなる群から選択される1種又は2種以上を含有する、請求項1に記載の貼付剤。
- 液状成分として、不揮発性炭化水素油と、不揮発性炭化水素油以外の液状成分とを含有する、請求項1に記載の貼付剤。
- 不揮発性炭化水素油が流動パラフィンである、請求項2または3に記載の貼付剤。
- 不揮発性炭化水素油以外の液状成分として、液状の界面活性剤、エステル系溶媒、アルコール系溶媒およびアミド系溶媒よりなる群から選択される1種又は2種以上を含有する、請求項3に記載の貼付剤。
- 不揮発性炭化水素油以外の液状成分として、エステル系溶媒の1種または2種以上と、アルコール系溶媒およびアミド系溶媒よりなる群から選択される1種又は2種以上とを含有する、請求項3に記載の貼付剤。
- 液状の界面活性剤が液状のソルビタン脂肪酸エステルである、請求項2または5に記載の貼付剤。
- 粘着層中の液状成分の含有量が60重量%以上である、請求項1~7のいずれか1項に記載の貼付剤。
- 熱可塑性エラストマーがスチレン系ブロック共重合体である、請求項1~8のいずれか1項に記載の貼付剤。
- スチレン系ブロック共重合体が、スチレン-イソプレン-スチレンブロック共重合体およびスチレン-イソプレンブロック共重合体よりなる群から選択される1種又は2種以上である、請求項9に記載の貼付剤。
- 粘着層中に粘着付与剤を含まない、請求項1~10のいずれか1項に記載の貼付剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/239,475 US20140303189A1 (en) | 2011-08-19 | 2012-08-17 | Patch |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011179988 | 2011-08-19 | ||
JP2011-179988 | 2011-08-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013027681A1 true WO2013027681A1 (ja) | 2013-02-28 |
Family
ID=47746424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/070933 WO2013027681A1 (ja) | 2011-08-19 | 2012-08-17 | 貼付剤 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20140303189A1 (ja) |
JP (1) | JPWO2013027681A1 (ja) |
WO (1) | WO2013027681A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2614819A1 (en) * | 2010-09-03 | 2013-07-17 | KM Transderm | Percutaneous absorbent and adhesive sheet for skin patch |
WO2014051128A1 (ja) * | 2012-09-28 | 2014-04-03 | 株式会社 ケイ・エム トランスダーム | 貼付剤 |
JP2021001147A (ja) * | 2019-06-24 | 2021-01-07 | 興和株式会社 | 貼付剤 |
JP2021001146A (ja) * | 2019-06-24 | 2021-01-07 | 興和株式会社 | 貼付剤 |
EP3646874A4 (en) * | 2018-01-31 | 2021-03-17 | Unish Inc. | TRANSDERMAL PREPARATION OF PHOSPHATIDYLCHOLINE |
WO2023022097A1 (ja) * | 2021-08-17 | 2023-02-23 | 株式会社カネカ | 貼付剤、及びその製造方法 |
US11844763B2 (en) | 2014-04-17 | 2023-12-19 | Avenir Wellness Solutions, Inc. | Pharmaceutical composition and method of manufacturing |
US11890310B2 (en) | 2014-04-17 | 2024-02-06 | Avenir Wellness Solutions, Inc. | Pharmaceutical composition and method of manufacturing |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3744349A4 (en) * | 2018-01-22 | 2021-10-27 | Kaneka Corporation | ADHESIVE FILM FOR FIXING TO THE SKIN |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10316559A (ja) * | 1997-05-15 | 1998-12-02 | Sekisui Chem Co Ltd | 貼付剤 |
JP2006169238A (ja) * | 2004-11-22 | 2006-06-29 | Hisamitsu Pharmaceut Co Inc | 薬物含有貼付剤 |
WO2006093139A1 (ja) * | 2005-02-28 | 2006-09-08 | Hisamitsu Pharmaceutical Co., Inc. | 経皮吸収製剤 |
JP2007217313A (ja) * | 2006-02-15 | 2007-08-30 | Hisamitsu Pharmaceut Co Inc | 凝集力向上及び徐放化の外用貼付剤 |
JP2008169145A (ja) * | 2007-01-11 | 2008-07-24 | Kotobuki Seiyaku Kk | 経皮適用製剤 |
-
2012
- 2012-08-17 US US14/239,475 patent/US20140303189A1/en not_active Abandoned
- 2012-08-17 WO PCT/JP2012/070933 patent/WO2013027681A1/ja active Application Filing
- 2012-08-17 JP JP2013530005A patent/JPWO2013027681A1/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10316559A (ja) * | 1997-05-15 | 1998-12-02 | Sekisui Chem Co Ltd | 貼付剤 |
JP2006169238A (ja) * | 2004-11-22 | 2006-06-29 | Hisamitsu Pharmaceut Co Inc | 薬物含有貼付剤 |
WO2006093139A1 (ja) * | 2005-02-28 | 2006-09-08 | Hisamitsu Pharmaceutical Co., Inc. | 経皮吸収製剤 |
JP2007217313A (ja) * | 2006-02-15 | 2007-08-30 | Hisamitsu Pharmaceut Co Inc | 凝集力向上及び徐放化の外用貼付剤 |
JP2008169145A (ja) * | 2007-01-11 | 2008-07-24 | Kotobuki Seiyaku Kk | 経皮適用製剤 |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2614819A1 (en) * | 2010-09-03 | 2013-07-17 | KM Transderm | Percutaneous absorbent and adhesive sheet for skin patch |
EP2614819A4 (en) * | 2010-09-03 | 2014-04-23 | Km Transderm | PERCUTANEOUS ABSORBENT AND ADHESIVE SHEET FOR TRANSDERMAL STAMP |
WO2014051128A1 (ja) * | 2012-09-28 | 2014-04-03 | 株式会社 ケイ・エム トランスダーム | 貼付剤 |
US9895320B2 (en) | 2012-09-28 | 2018-02-20 | KM Transderm Ltd. | Transdermal patch with different viscosity hydrocarbon oils in the drug layer and the adhesive layer |
US11844763B2 (en) | 2014-04-17 | 2023-12-19 | Avenir Wellness Solutions, Inc. | Pharmaceutical composition and method of manufacturing |
US11890310B2 (en) | 2014-04-17 | 2024-02-06 | Avenir Wellness Solutions, Inc. | Pharmaceutical composition and method of manufacturing |
US11938160B2 (en) | 2014-04-17 | 2024-03-26 | Avenir Wellness Solutions, Inc. | Pharmaceutical composition and method of manufacturing |
EP3646874A4 (en) * | 2018-01-31 | 2021-03-17 | Unish Inc. | TRANSDERMAL PREPARATION OF PHOSPHATIDYLCHOLINE |
US11202763B2 (en) | 2018-01-31 | 2021-12-21 | Unish Inc. | Phosphatidylcholine transdermal absorption preparation |
JP2021001146A (ja) * | 2019-06-24 | 2021-01-07 | 興和株式会社 | 貼付剤 |
JP2021001147A (ja) * | 2019-06-24 | 2021-01-07 | 興和株式会社 | 貼付剤 |
JP7412906B2 (ja) | 2019-06-24 | 2024-01-15 | 興和株式会社 | 貼付剤 |
WO2023022097A1 (ja) * | 2021-08-17 | 2023-02-23 | 株式会社カネカ | 貼付剤、及びその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2013027681A1 (ja) | 2015-03-19 |
US20140303189A1 (en) | 2014-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013027681A1 (ja) | 貼付剤 | |
JP6467726B2 (ja) | 貼付剤 | |
US9895320B2 (en) | Transdermal patch with different viscosity hydrocarbon oils in the drug layer and the adhesive layer | |
JP6089339B2 (ja) | 経皮吸収製剤 | |
JP5404048B2 (ja) | 貼付剤 | |
WO2019142940A1 (ja) | 皮膚貼付用粘着シート | |
JP2021130693A (ja) | 経皮吸収製剤 | |
WO2013081014A1 (ja) | 貼付剤 | |
WO2014181840A1 (ja) | 貼付剤 | |
WO2013133388A1 (ja) | 貼付剤 | |
JP6182744B2 (ja) | ナルフラフィン含有経皮吸収貼付剤 | |
JP2013184976A (ja) | 貼付剤 | |
CN105939718B (zh) | 含依美斯汀的贴剂 | |
WO2016208729A1 (ja) | ナルフラフィン含有経皮吸収貼付剤 | |
JP2013184978A (ja) | 貼付剤 | |
JP6235407B2 (ja) | フェンタニル含有貼付剤 | |
JP6002055B2 (ja) | 貼付剤 | |
JP6864968B2 (ja) | 貼付剤 | |
TWI626953B (zh) | Percutaneous absorption preparation | |
WO2013133387A1 (ja) | 貼付剤 | |
TW201400149A (zh) | 經皮吸收型製劑 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12825589 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2013530005 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14239475 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12825589 Country of ref document: EP Kind code of ref document: A1 |